Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY K VAUGHT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1194770339
CMS profile
99094
Location
CRAB ORCHARD, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$162,379.00

430 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 9; records 101–150 of 430 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY K VAUGHT

NPI 1194770339 · CMS profile ID 99094

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CRAB ORCHARD, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 9; records 101–150 of 430 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194770339?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY K VAUGHT, NPI 1194770339, CMS profile ID 99094. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 430 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194770339?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BARRY K VAUGHT, NPI 1194770339, CMS profile ID 99094. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 430 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194770339?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BARRY K VAUGHT, NPI 1194770339, CMS profile ID 99094, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 9; records 101–150 of 430 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194770339?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

430 matching records · $162,379.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 430 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 430.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $400.0010/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203977 CMS
Greenwich Biosciences, Inc. $21.9810/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701787919 CMS
Novartis Pharmaceuticals Corporation $66.5710/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659989725 CMS
Sunovion Pharmaceuticals Inc. $2.0810/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692373535 CMS
Novartis Pharmaceuticals Corporation $10.2310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659989715 CMS
Teva Pharmaceuticals USA, Inc. $9.3710/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697735455 CMS
Amgen Inc. $84.6410/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203973 CMS
Amgen Inc. $8.0010/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203979 CMS
Avanir Pharmaceuticals, Inc. $10.8510/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653608991 CMS
GENZYME CORPORATION $11.9710/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694225409 CMS
Amgen Inc. $68.0710/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203971 CMS
UCB, Inc. $12.6510/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688306499 CMS
Acorda Therapeutics, Inc $156.6010/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509427 CMS
Acorda Therapeutics, Inc $16.5310/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509429 CMS
Acorda Therapeutics, Inc $0.8010/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509431 CMS
Avanir Pharmaceuticals, Inc. $2,400.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653608985 CMS
Acorda Therapeutics, Inc $2,750.0010/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509425 CMS
Supernus Pharmaceuticals, Inc. $14.3210/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702366253 CMS
Avanir Pharmaceuticals, Inc. $12.3309/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653608655 CMS
Avanir Pharmaceuticals, Inc. $294.5209/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653608983 CMS
Amgen Inc. $2.0009/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203901 CMS
Avanir Pharmaceuticals, Inc. $124.9909/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653608657 CMS
Upsher-Smith Laboratories LLC $16.4509/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679939513 CMS
Amgen Inc. $21.6909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203875 CMS
Biogen, Inc. $20.1809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660602723 CMS
Acorda Therapeutics, Inc $12.4609/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509423 CMS
Amgen Inc. $2,400.0009/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203907 CMS
Amgen Inc. $400.0009/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203913 CMS
Sunovion Pharmaceuticals Inc. $8.8909/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692373537 CMS
Amgen Inc. $21.8809/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203919 CMS
Amgen Inc. $16.0009/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203925 CMS
Amgen Inc. $135.7209/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203931 CMS
Genentech USA, Inc. $14.3109/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681351017 CMS
Acorda Therapeutics, Inc $2,750.0009/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509413 CMS
Acorda Therapeutics, Inc $158.9209/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509415 CMS
Acorda Therapeutics, Inc $13.3509/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509417 CMS
Acorda Therapeutics, Inc $16.0009/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509419 CMS
Acorda Therapeutics, Inc $15.9909/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633509421 CMS
Amgen Inc. $800.0009/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203909 CMS
Amgen Inc. $32.7209/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203915 CMS
Amgen Inc. $16.0009/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203921 CMS
Amgen Inc. $370.0409/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203927 CMS
Amgen Inc. $2,400.0009/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203935 CMS
Amgen Inc. $2,400.0009/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203937 CMS
Scilex Pharmaceuticals Inc. $22.0109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689482813 CMS
EMD Serono, Inc. $13.2509/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702998291 CMS
Sunovion Pharmaceuticals Inc. $6.7509/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692373539 CMS
Amgen Inc. $64.9609/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203891 CMS
Amgen Inc. $23.3509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662203899 CMS
EMD Serono, Inc. $33.4709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702962579 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $162,379.00 430
PY2020 $117,787.09 350
PY2021 $172,313.53 472
PY2022 $275,612.46 499
PY2023 $210,916.27 489
PY2024 $261,464.97 519
PY2025 $241,236.20 522

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $333,925.07 29
PY2024 Principal investigator $338,026.06 19
PY2023 Recipient $3,853.00 2
PY2023 Principal investigator $380,223.05 40
PY2022 Principal investigator $322,461.35 345
PY2021 Principal investigator $182,961.10 184
PY2020 Recipient $3,000.00 1
PY2020 Principal investigator $6,068.94 2
PY2019 Recipient $10,000.00 4
PY2019 Principal investigator $1,222.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202533941
Principal investigator 1 ABBVIE INC. $1,805.00 12/04/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528062
Principal investigator 1 ABBVIE INC. $5,835.00 11/05/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522211
Principal investigator 1 Novartis Pharmaceuticals Corporation $134.11 10/28/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308246
Principal investigator 1 ABBVIE INC. $5,430.00 10/09/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202515185
Principal investigator 1 Amgen Inc. $1,180.00 09/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246641189
Principal investigator 1 ABBVIE INC. $4,730.00 09/04/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509124
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,754.89 08/19/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308248
Principal investigator 1 ABBVIE INC. $1,805.00 08/06/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503279
Principal investigator 1 ABBVIE INC. $3,610.00 07/02/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496415
Principal investigator 1 Amgen Inc. $82,287.00 06/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246641131
Principal investigator 1 Amgen Inc. $16,287.95 06/23/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246651170
Principal investigator 1 UCB SA $10,729.00 06/05/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658726
Principal investigator 1 ABBVIE INC. $5,430.00 06/03/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202489447
Principal investigator 1 Amgen Inc. $5,546.40 04/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246641187
Principal investigator 1 Celgene Corporation $4,000.00 04/09/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 1222306219
Principal investigator 1 ABBVIE INC. $3,610.00 04/03/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202473919
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $788.00 04/02/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
ITI-214-202 No dispute reported 06/30/2026 1242338861
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 03/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
ITI-214-202 No dispute reported 06/30/2026 1242335052
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,940.00 03/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
ITI-214-202 No dispute reported 06/30/2026 1242335054
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 03/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
ITI-214-202 No dispute reported 06/30/2026 1242335056
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $13,200.00 03/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
ITI-214-202 No dispute reported 06/30/2026 1242335058
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,500.00 03/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
ITI-214-202 No dispute reported 06/30/2026 1242335108
Principal investigator 1 UCB SA $14,885.20 02/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246657560
Principal investigator 1 AstraZeneca UK Limited $25,016.10 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185544281
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,810.20 01/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190309648
Principal investigator 1 Amgen Inc. $7,380.78 01/23/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246651179
Principal investigator 1 Amgen Inc. $11,856.61 01/02/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246651175
Principal investigator 1 Novartis Pharmaceuticals Corporation $77,273.83 01/02/2025 Non-covered Recipient Entity
VAUGHT NEUROLOGICAL SERVICES PLLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190312061